Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

Cumberland Pharmaceuticals Inc. announced today that data from two key clinical trials for Caldolor®, an intravenous formulation of ibuprofen approved for treatment of pain and fever in adults, will be presented at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting to be held in Phoenix, Ariz., on October 8-11, 2009.

5 Oct 2009

Baptist Healthcare System deploys Mckesson's Horizon Enterprise Revenue Management solution

Kentucky-based Baptist Healthcare System plans to stay ahead of the information technology curve. When a switch was flipped on Aug. 15 at Baptist Hospital Northeast in La Grange, Ky., the health system became the first to simultaneously implement both the access and business management modules of McKesson’s Horizon Enterprise Revenue Management™ solution.

5 Oct 2009

70% of Americans underestimate the seriousness of SCA

More than 250,000 deaths occur each year as a result of sudden cardiac arrest (SCA). In fact, SCA claims one life every two minutes, taking more lives each year than breast cancer, lung cancer or AIDS. Yet, according to a recent survey issued by the Heart Rhythm Society, more than 70 percent of Americans not only underestimate the seriousness of SCA, but also believe SCA is a type of heart attack.

3 Oct 2009

USPTO grants Micardia's patent concerning reshaping the anatomy of the heart

MiCardia® today announced that The United States Patent Office granted patent number US7,594,887 B2, "Shape Memory Devices and Methods for Reshaping Heart Anatomy," on September 29th, 2009.

3 Oct 2009

FDA grants Fast Track designation to Corthera's relaxin for treating acute heart failure

Corthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to relaxin, the company's investigational drug for the treatment of acute heart failure (AHF). The Fast Track program facilitates the development and expedites the review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

3 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

1 Oct 2009

Consumption of fish has no major role in protection against heart failure

The consumption of fish has no major role in the prevention of heart failure, according to results from a large prospective population study. The study, which was started in 1990 and involved all men and women over the age of 55 living in a suburb of Rotterdam, found no difference in the risk of developing heart failure between those who did eat fish and those who didn't.

1 Oct 2009

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for cardiac patients. The stem cells aid in limiting damage due to a cardiac event and promote angiogenesis or formation of new blood vessels.

1 Oct 2009

Houston Northwest Medical Center recognized as Cycle III Chest Pain Center with PCI

In its continuous pursuit of quality cardiac care, Houston Northwest Medical Center was proudly recognized as the first accredited chest pain center in Houston and one of a handful in Texas to be named a Cycle III Chest Pain Center with PCI (percutaneous coronary intervention).

30 Sep 2009

Orphan drug designation for pixantrone applied by Cell Therapeutics

Cell Therapeutics, Inc. ("CTI") announced today that it has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL.

30 Sep 2009

St. Jude Medical launches new cardiac rhythm management devices

St. Jude Medical, Inc. today announced it has launched several new cardiac rhythm management devices for the treatment and diagnosis of abnormal heart rhythms.

30 Sep 2009

CIHR and CMAJ honour eight Canadian Health Researchers

The Canadian Institutes of Health Research (CIHR) and the Canadian Medical Association Journal (CMAJ) today honoured eight outstanding Canadian individuals and teams with the first ever CIHR-CMAJ Top Canadian Achievements in Health Research Awards, which recognize and celebrate Canadian health research and innovation excellence.

29 Sep 2009

Hospital-at-home care favorable to traditional hospital care

Hospital-at-home care may be a practical alternative to traditional hospital inpatient care for patients with acutely decompensated (suddenly worsening) chronic heart failure, according to a report in the September 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

Study links diabetes to atrial fibrillation in women

Diabetes increases by 26 percent the likelihood that women will develop atrial fibrillation (AF), a potentially dangerous irregular heart rhythm that can lead to stroke, heart failure, and chronic fatigue. These are the findings of a new Kaiser Permanente study, published in the October issue of Diabetes Care, a journal of the American Diabetes Association.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Research to develop small-molecule drug that blocks excess iron absorption

Excess iron in the body, if left unchecked, can form toxic deposits in major organs leading to serious conditions including heart failure, diabetes, liver cirrhosis, arthritis, and even infertility. Iron overload can be a consequence of a genetically mutated gene known as hereditary hemochromatosis, or a consequence of red blood cell transfusions, required as life saving treatments, for patients with diseases such as thalassemia.

25 Sep 2009

Matrix metalloproteinase-8 enzyme increases the risk of heart diseases

Scientists at Queen Mary, University of London have made an important discovery in understanding what causes arteries to clog up. They have discovered that an enzyme called matrix metalloproteinase-8 plays a crucial role in raising blood pressure and causing abnormal build-up of cells in the arteries - both of which increase the risk of heart disease.

25 Sep 2009

$Cardiogenesis sponsors educational symposium on refractory angina treatment method$

Cardiogenesis sponsors educational symposium on refractory angina treatment method

Cardiogenesis Corporation, a market leader in laser transmyocardial revascularization (TMR), today announced that it sponsored an educational symposium yesterday in conjunction with the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.

24 Sep 2009

Heart Failure News and Research

Further Reading

Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

Baptist Healthcare System deploys Mckesson's Horizon Enterprise Revenue Management solution

70% of Americans underestimate the seriousness of SCA

USPTO grants Micardia's patent concerning reshaping the anatomy of the heart

FDA grants Fast Track designation to Corthera's relaxin for treating acute heart failure

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

Consumption of fish has no major role in protection against heart failure

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Houston Northwest Medical Center recognized as Cycle III Chest Pain Center with PCI

Orphan drug designation for pixantrone applied by Cell Therapeutics

St. Jude Medical launches new cardiac rhythm management devices

CIHR and CMAJ honour eight Canadian Health Researchers

Hospital-at-home care favorable to traditional hospital care

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Study links diabetes to atrial fibrillation in women

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Research to develop small-molecule drug that blocks excess iron absorption

Matrix metalloproteinase-8 enzyme increases the risk of heart diseases

Cardiogenesis sponsors educational symposium on refractory angina treatment method

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News